ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation by Jun, H J et al.
ERCC1 expression as a predictive marker of squamous cell
carcinoma of the head and neck treated with cisplatin-based
concurrent chemoradiation
HJ Jun
1, MJ Ahn
1, HS Kim
1,S YY i
1, J Han
2,S KL e e
3, YC Ahn
4, H-S Jeong
5, Y-I Son
5, J-H Baek
5 and K Park*,1
1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710,
Korea;
2Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea;
3Department of
Pathology, Kangwon National University Hospital, Kangwon National University School of Medicine, Kangwon-do 200-947, Korea;
4Department of
Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea;
5Department of Head and Neck
Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea
The excision repair cross-complementation group 1 (ERCC1) enzyme plays a rate-limiting role in the nucleotide excision repair
pathway and is associated with resistance to platinum-based chemotherapy. The purpose of this study was to evaluate the role of
ERCC1 expression as a predictive marker of survival in patients with locally advanced squamous cell carcinoma of the head and neck
(SCCHN) treated with cisplatin-based concurrent chemoradiotherapy (CCRT). ERCC1 expression was assessed by
immunohistochemical staining. The median age of the 45 patients analysed was 56 years (range 27–75 years), and 82% were
men; 73% of all specimens showed high expression of ERCC1. The overall tumour response rate after CCRT was 89%. The median
follow-up was 53.6 months (95% CI, 34.5–72.7 months). The 3-year progression-free survival (PFS) and overall survival (OS) rates
were 58.7 and 61.3%, respectively. Univariate analyses showed that patients with low expression of ERCC1 had a significantly higher
3-year PFS (83.3 vs 49.4%, P¼0.036) and OS (91.7 vs 45.5%, P¼0.013) rates. Multivariate analysis showed that low expression of
ERCC1 was an independent predictor for prolonged survival (HR, 0.120; 95% CI, 0.016–0.934, P¼0.043). These results suggest that
ERCC1 expression might be a useful predictive marker of locally advanced SCCHN in patients treated with cisplatin-based CCRT.
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Squamous cell carcinoma of the head and neck (SCCHN) accounts
for over 6% of all malignancies (Globocan, 2000) and most patients
present with locally advanced disease. Recent trials reported
improved locoregional control and overall survival (OS) by adding
chemotherapy to radiotherapy concurrently (Brizel et al, 1998;
Forastiere et al, 2003). The value of concurrent chemoradiotherapy
(CCRT) is counterbalanced by increased therapy-associated
complication rates. Therefore, identifying molecular markers that
can predict which patients benefit from CCRT is crucial in the
management of patients with locally advanced SCCHN.
Cisplatin is the backbone of the chemotherapy regimen as
a component of CCRT in the treatment of locally advanced
SCCHN. Its main cytotoxic activity is based on the formation of
DNA adducts, which cause inter- and intrastrand cross-linking.
The nucleotide excision repair pathway is considered as one of the
most important pathways that guard the integrity of the genome by
recognising and removing a variety of DNA cross-links caused by
cisplatin or radiation (Dabholkar et al, 1994; Murray and
Rosenberg, 1996). Excision repair cross-complementation group
1 (ERCC1) plays a key role in nucleotide excision repair and in
removing platinum-induced DNA adducts (Johnson et al, 2001). A
correlation between increased ERCC1 expression with resistance to
cisplatin or with poor survival has been reported for several
tumours including SCCHN (Metzger et al, 1998; Shirota et al, 2001;
Joshi et al, 2005; Handra-Luca et al, 2007). Polymorphisms in
metabolic enzymes and in DNA repair genes are related to the
treatment response in lung (Rosell et al, 2002), cervical (Britten
et al, 2000), colon (Viguier et al, 2005), and other (Yu et al, 1997;
Zhou et al, 2004) cancers.
Radiotherapy also injures genetic material and increases
apoptosis in tumour cells. Genetic polymorphisms in DNA repair
genes may significantly influence the response to radiotherapy in
stage I–II head and neck cancer (Carles et al, 2006).
The purpose of this study was to evaluate whether the
immunohistochemical expression status of ERCC1 can predict
the tumour response and cancer-specific survival in patients with
locally advanced SCCHN being treated with cisplatin-based CCRT.
MATERIALS AND METHODS
Patients and treatment
A total of 60 patients with histologically or cytologically proven
locally advanced SCCHN were treated with CCRT between 1995
and 2005 at Samsung Medical Center (Seoul, Korea). Forty-five
samples adequate for analysis of ERCC1 expression were enrolled
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sin this study. The performance status was ECOG 0–1. Inclusion
criteria included patients with adequate bone marrow, liver, and
renal function. None of the patients had prior radiotherapy or
chemotherapy.
The chemotherapy regimens comprised cisplatin with or with-
out 5-fluorouracil or taxane. The radiation dose was 72Gy over 7
weeks (2Gyday
 1, 5 fractions per week). Pretreatment evaluation
included the patient’s history, physical examination, performance
status, chest X-ray, complete blood count, blood chemistry, and
computed tomography (CT) scan or magnetic resonance imaging
(MRI) of the head and neck. The response to CCRT was assessed
according to the World Health Organization (WHO) criteria.
Patients were evaluated by CT scan or MRI of the head and neck
every 3 months for 2 years, and then every 6 months thereafter.
Approval was obtained from the Institutional Review Boards,
according to legal regulations.
Immunohistochemical staining for ERCC1
Formalin-fixed paraffin-embedded tissue blocks were sectioned at
4mm thickness. The tissue sections were deparaffinised in xylene
and then rehydrated in serial-graded alcohol. Excision repair
cross-complementation group 1 antigen retrieval comprised
heating in 10mM citrate buffer at pH 6.0 in a microwave
(15min, 700W) and cooling at room temperature for 20min.
The sections were washed in Tris-buffered saline (TBS), and the
slides were pre-incubated with 5% normal blocking solution (goat
serum) for 10min to reduce nonspecific binding. The slides were
incubated at room temperature with mouse monoclonal anti-
ERCC1 (8F1; Neomarkers, Fremont, CA, USA) (Wachters et al,
2005; Olaussen et al, 2006; Handra-Luca et al, 2007) at a dilution of
1:200 overnight in a humidified chamber. The primary antibody
was visualised with an avidin–biotin complex (ABC) system
(Dako, Carpinteria, CA, USA). The slides were washed in TBS, the
relevant biotinylated goat anti-mouse IgG diluted at 1:100 was
added, and the slides were incubated for 20min at room
temperature. The sections were washed again in TBS and
incubated for 10min in a solution of streptavidin–ABC–horse-
radish peroxidase diluted at 1:100. Colour was developed by
adding 3,30-diaminobenzidine tetrahydrochloride (Immunotech,
Cedex, France). Finally, the sections were counterstained with
Mayer’s haematoxylin.
Evaluation of ERCC1 expression
Two pathologists (JH and SKL), who were unaware of the clinical
data, evaluated the ERCC1 staining independently under a light
microscope at a magnification of  400. The pathologists recorded
Table 1 Characteristics of patients
All patients (N¼45) Low ERCC1 (N¼12) High ERCC1 (N¼33)
Characteristics Number (%) P-value
Age (years) 0.283
p60 30 (67) 10 (83) 20 (61)
460 15 (33) 2 (17) 13 (39)
Sex 0.022
Male 37 (82) 7 (58) 30 (91)
Female 8 (18) 5 (42) 3 (9)
T stage 0.699
T1–T2 11 (24) 2 (17) 9 (27)
T3–T4 34 (76) 10 (83) 24 (73)
N stage 0.743
N0–N1 17 (38) 5 (42) 12 (36)
N2–N3 28 (62) 7 (58) 21 (64)
Stage 1.000
III 8 (18) 2 (17) 6 (18)
IVA 30 (67) 8 (66) 22 (67)
IVB 7 (15) 2 (17) 5 (15)
Location 0.044
Paranasal sinus 5 (11) 3 (25) 2 (6)
Oral cavity 5 (11) 1 (8) 4 (12)
Oropharynx 15 (33) 5 (42) 10 (30)
Hypopharynx 12 (27) 0 (0) 12 (36)
Larynx 8 (18) 3 (25) 5 (15)
Performance status 0.705
0 12 (27) 4 (33) 8 (24)
1 33 (73) 8 (67) 25 (76)
Smoking 0.013
Yes 35 (78) 6 (50) 29 (88)
No 10 (22) 6 (50) 4 (12)
Alcohol 0.283
Yes 30 (67) 6 (50) 24 (73)
No 15 (33) 6 (50) 9 (27)
ERCC1¼excision repair cross-complementation group 1.
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swhether tumour or stromal cells expressed ERCC1. The staining
intensity was graded on a scale of 0–3; endothelial cells were used
as the internal reference and assigned an intensity of 2. Five images
of representative areas were acquired for each specimen. A total of
500–1500 positive or negative tumour nuclei per specimen were
counted manually on a computer screen. The percentage of
positive nuclei was calculated for each specimen, and a proportion
score was assigned (0 if 0%, 0.1 if 1–9%, 0.5 if 10–49%, and 1.0 if
X50%). The proportion score was multiplied by the staining
intensity to obtain a final semi-quantitative H score. The median
value of the H score was chosen as the cutoff point for separating
low and high levels of ERCC1 expression, as described previously
(Olaussen et al, 2006).
Statistical analysis
The baseline characteristics of the low and high levels of ERCC1
expression groups of patients were compared using the Fisher’s
exact test for discrete variables and the Mann–Whitney U-test for
continuous variables. The OS duration was calculated from the
first day of the CCRT until the date of death or the latest
documented follow-up. Progression-free survival (PFS) was
calculated from the first day of the CCRT to the day when the
disease progression was recognised or the day of the last follow-up
visit. Survival rates were estimated using the Kaplan–Meier
method. The prognostic value of ERCC1 status was studied using
Cox models adjusted for known prognostic factors, such as age,
tumour location, and TNM stage. All reported P-values are two-
sided and Po0.05 was considered significant.
RESULTS
Patient characteristics
The median age of the patients was 56 years (range 27–75 years),
and 82% were men. Eight patients had stage III, 30 had stage IVA,
and seven had stage IVB disease. The most common sites were the
oropharynx (15 out of 45, 33%), followed by the hypopharynx (12
out of 45, 27%) (Table 1). Of the 45 patients who initially entered
into the study, 17 patients were treated with cisplatin only (38%); 6
with 5-fluorouracil plus cisplatin (13%); and 22 with taxane plus
cisplatin (49%). The median dose of administered cisplatin was
225mgm
 2 (range 60–300mgm
 2) and the median radiation was
6660cGy (range 3960–7200cGy). Twenty patients received more
than 70Gy of radiation dose and 38 patients completed the
planned chemotherapy.
Clinical–pathological data and ERCC1 expression
Excision repair cross-complementation group 1 expression was
localised to the nucleus, and the median H score for SCCHN
tumours was 2.0 (Figure 1). Thirty-three (73%) tumours with H
score X2.0 were defined as having high expression of ERCC1.
The clinical–pathological variables including age, TNM stage,
and performance status did not differ significantly between
patients with high and low expression of ERCC1 (Table 1). The
high ERCC1 expression group included more men (P¼0.022) and
more smokers (P¼0.013, Table 1). Squamous cell carcinoma of
the head and neck of the hypopharynx showed higher expression
of ERCC1.
Relationship between treatment response and ERCC1
expression
The overall response rate after CCRT for all patients was 89% (40
out of 45, 27 complete responses and 13 partial responses; 3 with
stable disease and 2 with progressive disease). Patients with low
expression of ERCC1 achieved a higher complete response (10 out
of 12, 83%) compared with 52% (17 out of 33) of patients with high
expression of ERCC1, although this was not significant (P¼0.086,
Table 2).
Relationship between survival and ERCC1 expression
The median follow-up was 53.6 months (95% CI, 34.5–72.7
months). The overall 3-year PFS rate was 58.7% (95% CI, 44.0–
73.4%) and the 3-year OS rate was 61.3% (95% CI, 45.4–77.2%).
The 3-year PFS for patients with low expression of ERCC1 was
83.3% (95% CI, 62.1–100.0%) compared with 49.4% (95% CI,
Figure 1 Representative examples of ERCC1 immunostains. (A) H
score o2. (B) H score X2. Original magnification,  400.
Table 2 Expression of ERCC1 and response to treatment
Low ERCC1
patients (N¼12)
High ERCC1
patients (N¼33)
Number (%) P-value
Response 0.010
Complete response 10 (83) 17 (52)
Partial response 0 (0) 13 (39)
Stable disease 2 (17) 1 (3)
Progression disease 0 (0) 2 (6)
ERCC1¼excision repair cross-complementation group 1.
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s31.8–67.0%) for patients with high expression of ERCC1
(P¼0.036, Figure 2A). The 3-year OS rate was significantly longer
in patients with low expression of ERCC1 (91.7; 95% CI, 76.0–
100.0%) than in those with high expression of ERCC1 (45.5; 95%
CI, 23.9–67.1%) (P¼0.013, Figure 2B). The univariate analysis
revealed that tumour stage, tumour location, and ERCC1 expres-
sion were important factors affecting the prolongation of both PFS
and OS (Table 3). The multivariate analysis also showed that low
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Figure 2 Kaplan–Meier estimates of the probability of survival. (A) PFS according to ERCC1 expression. (B) OS according to ERCC1 expression.
Table 3 Univariate analyses of prognostic factors for survival
3-year PFS 3-year OS
N¼45 N¼44
Percent (95% CI) P-value Percent (95% CI) P-value
Sex 0.580 0.336
Male 58.2 (41.9–74.5) 58.9 (40.9–76.9)
Female 62.5 (29.0–96.0) 72.9 (40.6–100.0)
Age (years) 0.572 0.687
p60 55.9 (37.9–73.9) 60.3 (41.9–78.7)
460 65.0 (40.1–89.9) 59.6 (22.4–96.8)
Smoking 0.702 0.481
Yes 58.7 (42.0–75.4) 60.2 (42.0–78.4)
No 60.0 (29.6–90.4) 66.7 (35.1–98.3)
Stage 0.002 0.003
III 75.0 (45.0–100.0) 83.3 (53.5–100.0)
IVA 68.9 (51.8–86.0) 70.7 (53.5–87.9)
IVB 0 0
Tumour location o0.001 o0.001
Oral cavity 0 0
Others 66.2 (51.1–81.3) 70.7 (54.8–86.6)
Performance status 0.491 0.986
0 50.0 (21.8–78.2) 66.7 (40.0–93.4)
1 62.0 (44.9–79.1) 60.3 (41.5–79.1)
ERCC1 expression 0.036 0.013
High 49.4 (31.8–67.0) 45.5 (23.9–67.1)
Low 83.3 (62.1–100.0) 91.7 (76.0–100.0)
Chemotherapy regimen 0.245 0.151
Cisplatin 46.0 (19.9–72.1) 49.7 (22.8–76.6)
Fluorouracil+cisplatin 50.0 (10.0–90.0) 50.0 (10.0–90.0)
Taxane+cisplatin 68.2 (48.8–87.6) 73.9 (53.5–94.3)
Completion of chemotherapy 0.192 0.078
Yes 61.6 (45.7–77.5) 65.6 (48.5–82.7)
No 42.9 (6.2–79.6) 42.9 (6.2–79.6)
Radiation dose (Gy) 0.296 0.381
p66.6 48.5 (27.9–69.1) 55.3 (34.3–76.3)
466.6 70.0 (50.0–90.0) 67.4 (42.3–92.5)
ERCC1¼excision repair cross-complementation group 1; OS¼overall survival; PFS¼progression-free survival.
ERCC1 in SCCHN after cisplatin-based CCRT
HJ Jun et al
170
British Journal of Cancer (2008) 99(1), 167–172 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sexpression of ERCC1 (HR 0.120; 95% CI, 0.016–0.934%)
(P¼0.043) together with tumours other than oral cavity primary
tumours (HR 0.168; 95% CI, 0.040–0.707) (P¼0.015), and stage III
tumours (HR 0.081; 95% CI, 0.009–0.716) (P¼0.024) were
independent predictors of the prolongation of OS (Table 4).
DISCUSSION
We found a high expression of ERCC1 in 73% of SCCHN tumours.
The median percentage of ERCC1-stained nuclei was 92%, and the
median H score was 2.0, values that are consistent with a previous
report (Handra-Luca et al, 2007). In contrast, in a study of non-
small-cell lung cancer (NSCLC), the median H score for ERCC1
expression was 1.0 and 30–40% of tumours expressed ERCC1
(Olaussen et al, 2006), suggesting that the proportion and pattern
of ERCC1 expression varies according to the tumour type. It is of
interest that in our study, specimens from men and smokers, and
the presence of SCCHN of the hypopharynx showed high
expression of ERCC1. These findings await confirmation by
prospective studies with large numbers of patients.
Patients with low expression of ERCC1 achieved a higher rate of
complete response to CCRT than did those with high expression of
ERCC1, although the overall response did not differ significantly. It
is noteworthy that ERCC1 expression was associated with a
significantly longer PFS and OS. The 3-year PFS for patients with
low expression of ERCC1 was 83.3% compared with 49.4% for
patients with high expression of ERCC1 (P¼0.036). The 3-year OS
rate was also significantly longer in patients with low expression of
ERCC1 than in patients with high expression of ERCC1 (91.7 vs
45.5%, P¼0.013). Multivariate analysis revealed that low expres-
sion of ERCC1 was an independent factor associated with a lower
risk of cancer death (HR 0.12, P¼0.043). This result is also
consistent with a previous report of an increase in tumour
response and prolongation of OS in patients treated by cisplatin-
based induction chemotherapy for locally advanced SCCHN
(Handra-Luca et al, 2007). Although the association between
ERCC1 expression and clinical outcomes in patients with SCCHN
treated with radiotherapy has not been established, in NSCLC, the
level of induced DNA adducts in buccal cells is strongly associated
with outcome after definitive concomitant low-dose cisplatin and
radiotherapy for stage IIIA/B NSCLC (van de Vaart et al, 2000). A
relationship between the expression of ERCC1 and tumour
response or survival was also reported in oesophageal cancer
patients treated with chemoradiotherapy (Warnecke-Eberz et al,
2004; Joshi et al, 2005). In this context, our findings provide
additive evidence that the pretreatment level of ERCC1 in tumour
cells is negatively related to the treatment outcome of platinum
compounds. The predictive role of pretreatment ERCC1 expression
level might be connected with the capacity for DNA damage repair,
that is, tumour cells with a more efficient DNA repair capacity can
be resistant to cisplatin-based chemotherapy or radiotherapy.
Further mechanistic study is needed to confirm this concept.
Quantitative real-time reverse transcription–PCR is commonly
used to detect ERCC1 expression (Dabholkar et al, 1994; Metzger
et al, 1998; Shirota et al, 2001; Lord et al, 2002). Although this
method is very sensitive and semi-quantitative, it requires fresh
tumour samples. A study to determine whether DNA polymorph-
ism of ERCC1 has predictive value in head and neck cancer
patients showed that polymorphic variation in DNA repair
genes (XPD and XRCC1, not ERCC1) is a powerful prognostic
factor for the response to cisplatin in SCCHN patients (Quintela-
Fandino et al, 2006). However, this polymorphism is associated
mainly with lower rates of translation of the ERCC1 gene, which
results in low levels of the protein in nucleus. Immunohistochem-
istry is a clinically feasible method that can be applied in almost
every pathology laboratory despite several limitations, including
the use of different antibodies, inter- or intraobserver variation,
and the variable cutoff value for ERCC1 positivity (Olaussen et al,
2006).
Our study has several limitations. First, the study analysed only 45
out of 60 patients with available tissues, and the analysis was based
on a retrospective analysis over a long time. During the study period,
advances in radiotherapy techniques, chemotherapeutic agents, and
supportive care may have affected the tumour response or survival.
Nevertheless, we found no significant difference in survival
according to the various chemotherapeutic agents. Second, the
primary tumour site was also heterogeneous, and the prognosis of
SCCHN is dependent on the primary tumour site: oral cavity cancer
has a worst prognosis and laryngeal cancer a good prognosis. We
also found that patients with oral cavity cancer had short PFS and
OS, each of which represented an independent prognostic factor.
Regardless, a high expression of ERCC1 was strongly correlated with
poor survival regardless of tumour location. Because our study
comprised only a small number of patients for each tumour location,
caution should be used when drawing conclusions from our data,
which need to be validated prospectively with more homogeneous
and a large number of patients.
In conclusion, this study suggests that ERCC1 expression levels
negatively contribute to the clinical outcomes including PFS and
OS in patients treated with cisplatin-based CCRT for locally
advanced SCCHN. This suggests that ERCC1 expression might be a
useful predictive marker.
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